EPEMED
EPEMED is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at EPEMED.
EPEMED is a company.
Key people at EPEMED.
Key people at EPEMED.
EPEMED (European Personalised Medicine Diagnostics Association) is a non-profit organization founded in 2009 to advance personalised medicine in Europe, emphasizing the critical role of advanced diagnostics and co-dependent drug-companion diagnostics in improving patient outcomes.[1][2][4] It serves as an independent catalyst, coordinating stakeholders—including industry, regulators, payers, governments, academia, and patient groups—to promote regulatory harmonization, reimbursement pathways, education, and broader adoption of value-based diagnostics across Europe.[1][2][5] EPEMED's mission focuses on making personalised medicine a reality for patients by fostering high-quality diagnostics, sharing insights via white papers, forums, and research, and addressing barriers in development and access.[1][2]
Unlike investment firms or startups, EPEMED operates as a dynamic platform without direct investments or products; instead, it influences the ecosystem by providing opinion leadership, harmonizing policies, and driving education on personalised medicine diagnostics.[2][4][6]
EPEMED was established in August 2009 as a not-for-profit association by European leaders in stratified medicine and diagnostics, with Alain Huriez, M.D., founder and chairman from TcLand Expression (a French molecular diagnostics company), at the helm.[1][2] Huriez, a key figure in molecular diagnostics, assembled a founding board of world-recognized experts to tackle exclusively European challenges in personalised medicine, filling a gap as the first such dedicated organization.[1][2][4]
The idea emerged amid growing innovations in molecular diagnostics, aiming to ensure these breakthroughs reach patients by promoting value pricing, reimbursement, and regulatory clarity.[2] Early focus centered on education for public, governments, and private sectors, evolving into broader activities like subcommittees on regulatory, economic, and educational issues.[1][2]
EPEMED stands out in the personalised medicine landscape through:
EPEMED rides the wave of personalised medicine's rise, leveraging genomics, biomarkers, and AI-driven diagnostics to shift healthcare from one-size-fits-all to tailored treatments amid Europe's aging population and rising chronic disease burdens.[1][2][7] Timing is ideal post-2009 founding, aligning with EU initiatives like Horizon 2020 and ICPERMed, where market forces favor value-based care amid reimbursement pressures and regulatory fragmentation.[3][7]
It influences the ecosystem by bridging silos—e.g., co-development of diagnostics and therapies—accelerating adoption and making Europe attractive for innovation, while complementing bodies like EP PerMed in policy and funding alignment.[3][6][7]
EPEMED is poised to expand influence as personalised medicine matures, potentially leading joint EU programs on AI-integrated diagnostics, sustainable reimbursement models, and global harmonization amid post-pandemic health reforms. Trends like real-world evidence demands and multi-omics will shape its path, amplifying its role in policy via partnerships. Its evolution from education pioneer to implementation driver positions it to sustain momentum in delivering diagnostics-driven patient gains, reinforcing its founding vision of breakthrough access.[1][2][8]
